Short term treatment with low doses of glucocorticoid analogues has been shown to ameliorate neurological symptoms in Ataxia–Telangiectasia (A–T), a rare autosomal recessive multisystem disease that mainly affects the cerebellum, immune system, and lungs. Molecular mechanisms underlying this clinical observation are unclear. We aimed at evaluating the effect of dexamethasone on the induction of alternative ATM transcripts (ATMdexa1). We showed that dexamethasone cannot induce an alternative ATM transcript in control and A–T lymphoblasts and primary fibroblasts, or in an ATM-knockout HeLa cell line. We also demonstrated that some of the reported readouts associated with ATMdexa1 are due to cellular artifacts and the direct induction of γH2AX by dexamethasone via DNA-PK. Finally, we suggest caution in interpreting dexamethasone effects in vitro for the results to be translated into a rational use of the drug in A–T patients.

In vitro dexamethasone treatment does not induce alternative ATM transcripts in cells from Ataxia–Telangiectasia patients

Pozzi E.;Giorgio E.;Mancini C.;Lo Buono N.;Augeri S.;Ferrero M.;Di Gregorio E.;Riberi E.;Bianchi F. T.;Funaro A.;Cavalieri S.;Brusco A.
2020

Abstract

Short term treatment with low doses of glucocorticoid analogues has been shown to ameliorate neurological symptoms in Ataxia–Telangiectasia (A–T), a rare autosomal recessive multisystem disease that mainly affects the cerebellum, immune system, and lungs. Molecular mechanisms underlying this clinical observation are unclear. We aimed at evaluating the effect of dexamethasone on the induction of alternative ATM transcripts (ATMdexa1). We showed that dexamethasone cannot induce an alternative ATM transcript in control and A–T lymphoblasts and primary fibroblasts, or in an ATM-knockout HeLa cell line. We also demonstrated that some of the reported readouts associated with ATMdexa1 are due to cellular artifacts and the direct induction of γH2AX by dexamethasone via DNA-PK. Finally, we suggest caution in interpreting dexamethasone effects in vitro for the results to be translated into a rational use of the drug in A–T patients.
10
1
8
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7677391/
ATM, ataxia talangiectasia, dexamethasone, alternative splicing
Pozzi E.; Giorgio E.; Mancini C.; Lo Buono N.; Augeri S.; Ferrero M.; Di Gregorio E.; Riberi E.; Vinciguerra M.; Nanetti L.; Bianchi F.T.; Sassi M.P.; Costanzo V.; Mariotti C.; Funaro A.; Cavalieri S.; Brusco A.
File in questo prodotto:
File Dimensione Formato  
161. ATM dexa_SciRep 2020.pdf

accesso aperto

Descrizione: Articolo principale
Tipo di file: PDF EDITORIALE
Dimensione 2.85 MB
Formato Adobe PDF
2.85 MB Adobe PDF Visualizza/Apri
161.suppl1.pdf

accesso aperto

Descrizione: Supplementari 1
Tipo di file: MATERIALE NON BIBLIOGRAFICO
Dimensione 467.96 kB
Formato Adobe PDF
467.96 kB Adobe PDF Visualizza/Apri
161. supp2.xlsx

accesso aperto

Descrizione: Supplementari 2
Tipo di file: DATASET
Dimensione 9.66 kB
Formato Microsoft Excel XML
9.66 kB Microsoft Excel XML Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2318/1764210
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact